In today’s briefing:
- China Healthcare Weekly (Feb16)-Innovative Drug Is “Innocent” In Geopolitics, BeiGene’s BTK, Jacobio
- DexCom Inc: Solid Market Penetration in Basal and Hypo Non-insulin markets & International Expansion Is Catalyzing Future Growth! – Major Drivers
- 2024 High Conviction Update: Asahi Intecc (7747 JP)- Strong H1 Performance; FY24 Guidance Reaffirmed
- Mettler-Toledo International: Is The China Market Recovery Saving The Day? – Major Drivers
- Waters Corporation: How Long Will The Upside From The Continuation of High-Level Trends and Geographical Growth Last? – Major Drivers
- Zimmer Biomet Holdings: Can It Maintain Its Robust Competitive Position In Orthopedics? – Major Drivers
- McKesson Corporation: Anticipated Revenue Growth in Medical-Surgical Solutions Could Propel Them Forward! – Major Drivers
China Healthcare Weekly (Feb16)-Innovative Drug Is “Innocent” In Geopolitics, BeiGene’s BTK, Jacobio
- Due to the US Draft Bill against CXOs, stock prices of the entire pharmaceutical industry plummeted. But in reality, there’s no impact on innovative drugs, which is just “emotional suppression”.
- The future BTK inhibitors market pattern predicted by GlobalData is very close to our estimate. This actually indirectly verifies the peak sales level that BeiGene may reach in the future.
- Setbacks on KRAS/SHP2 projects discourage investors’ confidence on Jacobio. We wouldn’t recommend projecting too high expectations on BET inhibitor just yet. Share price performance could continue to be under pressure.
DexCom Inc: Solid Market Penetration in Basal and Hypo Non-insulin markets & International Expansion Is Catalyzing Future Growth! – Major Drivers
- DexCom Inc., a medical device company focused on the design, development and delivery, presented its recorded Fourth quarter and Fiscal year 2023 earnings call.
- According to the call, the organization’s robust growth momentum has pivoted it towards notable accomplishments.
- The company reported that total revenue grew by 24% on an organic basis, implying a boon of over $700 million of organic revenue compared to the preceding year.
2024 High Conviction Update: Asahi Intecc (7747 JP)- Strong H1 Performance; FY24 Guidance Reaffirmed
- Asahi Intecc (7747 JP) announced better-than-expected result in H1FY24, with double-digit growth across all major parameters. Growth was driven by favorable Fx, recovery and expansion of cases, and strong demand.
- Revenue from medical division increased 22% YoY to ¥48B. Operating income of the medical division increased 52% YoY to ¥13B, representing 540bps YoY margin expansion to 27.3%.
- Asahi Intecc has not revised FY24 guidance as it is difficult to forecast currency movements and revenue from distributors in medical division due to volatility of quarterly transactions.
Mettler-Toledo International: Is The China Market Recovery Saving The Day? – Major Drivers
- The fourth quarter 2023 results posted by Mettler-Toledo, a Swiss precision instruments company, were significantly impacted by a transition to a new external European logistics service provider.
- The company confides in making up for the majority of the lost revenue in Q1 2024.
- Baptista Research looks to evaluate the different factors that could influence the company’s price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.
Waters Corporation: How Long Will The Upside From The Continuation of High-Level Trends and Geographical Growth Last? – Major Drivers
- In terms of positive outcomes, Waters Corporation reported another transformative year, demonstrating its resilience and ability to adapt effectively amidst a backdrop of dynamic market conditions.
- Various innovative products were launched throughout the year, such as the Alliance is next-generation LC platform, building on the successful top line growth delivered in previous years.
- The integration of Wyatt Technology into its portfolio represents a strategic move, bringing with it a new avenue for value creation for shareholders and opening up access to high growth markets.
Zimmer Biomet Holdings: Can It Maintain Its Robust Competitive Position In Orthopedics? – Major Drivers
- Zimmer Biomet, a leading player in the medical devices industry, presented its fourth quarter 2023 earnings with a buoyant attitude, displaying solid evidence of robust financial performance and operational progress.
- Impressively, the firm underscored the notable growth in its constant currency revenue, which appreciated 7.5%, with adjusted earnings per share (EPS) escalating almost 9.5% over the year.
- Also noteworthy was the almost $1 billion in free cash flow generated during the period, even amid fluctuations in inventory management.
McKesson Corporation: Anticipated Revenue Growth in Medical-Surgical Solutions Could Propel Them Forward! – Major Drivers
- McKesson Corporation, a diversified health care services company, reported robust fiscal third-quarter earnings during their recent earnings call.
- The business continues to show momentum with total revenues of $80.9 billion and adjusted earnings per diluted share of $7.74 exhibiting a double-digit growth year over year.
- This strong financial performance has been the result of a focused execution against the company’s long-term priorities.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
